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Introduction {#sec001}
============

About one quarter of Earth inhabitants are infected with parasitic helminths and most of them are living in Africa \[[@pntd.0008464.ref001]\]. In tropical and subtropical areas, soil-transmitted helminths (STH) are widely distributed, including *Ascaris lumbricoides*, *Trichuris trichiura* and hookworms, together with filarial nematodes and schistosomes such as *Schistosoma mansoni* and *Schistosoma haematobium* \[[@pntd.0008464.ref001], [@pntd.0008464.ref002]\]. Schistosomiasis affects 200 to 300 million people worldwide \[[@pntd.0008464.ref001]\], especially in the poorest regions of the low and middle income countries (LMIC), and remains a major public health problem in these endemic areas \[[@pntd.0008464.ref003], [@pntd.0008464.ref004]\], where it co-exists with other health condition, including non-communicable diseases (NCDs).

NCDs such as obesity, metabolic syndrome and type 2 diabetes (T2D) are increasing not only in industrialized countries but also in developing countries that experienced rapid rural-urban transition, notably in Africa \[[@pntd.0008464.ref005]--[@pntd.0008464.ref007]\]. In 2017, 16 million African people were estimated to have T2D, with a projected doubling of this number in the coming 20 years \[[@pntd.0008464.ref005]\]. Obesity is often associated with chronic low-grade inflammation, also called meta-inflammation, which contributes to peripheral and systemic insulin resistance, alterations of glucose and lipid metabolism, and ultimately leads to the development of T2D and related cardiovascular diseases \[[@pntd.0008464.ref008]\]. Meta-inflammation mostly results from alterations in the composition and/or activation state of a variety of innate and adaptive immune cells in metabolic organs, notably in adipose tissue and the liver, creating a pro-inflammatory environment that contribute to tissue-specific insulin resistance and whole-body metabolic dysfunctions \[[@pntd.0008464.ref009]\].

Chronic helminth infection is known to trigger a potent T~H~2 immune response together with T-cell hyporesponsiveness through induction of a regulatory network \[[@pntd.0008464.ref010]\], which have been both suggested to dampen meta-inflammation and restore tissue-specific and whole-body insulin sensitivity \[[@pntd.0008464.ref009]\]. Interestingly, helminth infection and treatment with helminth-derived molecules have also been shown to improve insulin sensitivity and glucose homeostasis in various rodent models of T2D, at least partly through induction of a type 2 immune response in metabolic organs \[[@pntd.0008464.ref011]\]. In line with this, epidemiological studies conducted in countries endemic for various helminth species have reported an inverse association between helminth infection and insulin resistance \[[@pntd.0008464.ref012]\] or incidence of metabolic syndrome and T2D \[[@pntd.0008464.ref013], [@pntd.0008464.ref014]\], suggesting a positive impact of helminths on host metabolic homeostasis. More recently, clinical interventional trials using anthelmintic drugs have also shown that deworming was associated with impaired systemic insulin sensitivity and glucose homeostasis in either STH-infected individuals or type 2 diabetic subjects with *Strongyloides stercoralis* infection, respectively \[[@pntd.0008464.ref015], [@pntd.0008464.ref016]\]. Nevertheless, the few human studies performed so far have mostly been done in STH-infected lean individuals, and principally focused on glucose rather than lipid homeostasis \[[@pntd.0008464.ref011]\]. As such, little is currently known on the impact of other helminth infection, notably with schistosomes, on metabolic homeostasis in people with a broad range of body weight. We have therefore conducted a cross-sectional study to investigate whether infection with *S*. *haematobium* could affect glucose and lipid homeostasis in lean and obese/overweight adult individuals living in endemic rural area.

Methods {#sec002}
=======

Ethics statement {#sec003}
----------------

The study was approved by the institutional ethics committee of the Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné, Gabon (Registered number: CEI-MRU 002/2014) and was conducted in line with the Good Clinical Practice principles of the International Conference on Harmonization and the Declaration of Helsinki.

Study site {#sec004}
----------

The study was conducted in Lambaréné region, an endemic area for *S*. *haematobium* in Gabon. The schistosomiasis prevalence among children and young adults was recently found to be 26% in Lambaréné village (Jean Claude Dejon-Agobé, personal communication) and 45% in the surrounding Zilé-PK area \[[@pntd.0008464.ref017], [@pntd.0008464.ref018]\].

Participants and study procedures {#sec005}
---------------------------------

Adult individuals (\>18 year-old) with either low/normal (\<25) or high (\>25) BMI and living in the study area were invited to join the study during on-site visit. An *a priori* power calculation was performed using mean serum TC levels from a previous small cohort study to determine the sample size allowing to detect a mean difference of \~12,5% between Sh^-^ and Sh^+^ group (α = 0.05; power = 80%). The recruitment was carried out from July 2014 to April 2015. At screening, anthropometric measurements were performed according to the NHLBI practical guidelines ([http://www.nhlbi.nih.gov](http://www.nhlbi.nih.gov/)). Eligible participants who provided urine, stool and blood samples were included for analysis. One sample of urine was collected during three consecutive days for the diagnosis of schistosomiasis. One stool sample was collected for assessing STH infection. Venous blood was collected between 8 and 10 am after an overnight-fast using S-Monovette EDTA tube (Sarstetd) for hematological analysis and BD Vacutainer SST II dry tubes (Beckton Dickinson) for serum biochemical analysis. Pregnant women (urinary β-HCG positive test), subjects with a family history of diabetes, non-diagnosed diabetic subjects (fasting serum glucose \>7 mM), anyone positive for *Plasmodium falciparum* parasites, and any participants negative for the presence of *S*. *haematobium* eggs in urine but infected with at least one other helminths were excluded from the study ([S1 Fig](#pntd.0008464.s001){ref-type="supplementary-material"}). At the end, 71 clinically healthy participants were included and two study groups were considered: a *S*. *haematobium* egg-positive (*Sh*^*+*^) group with all individuals clinically asymptomatic for schistosomiasis (n = 32), and a helminth negative (*Sh*^*-*^) group including participants negative for schistosomiasis and STH infection (n = 39). Individuals found positive for schistosomiasis (positive for urine eggs) and/or for STH infections (positive for stool eggs) were later treated with a single dose of 40 mg/kg praziquantel and/or with 400 mg of albendazole daily for three consecutive days, respectively, and those infected with *P*. *falciparum* were treated with 80/480 mg artemether/lumefantrine tablet twice a day during 3 consecutive days.

Parasitological examination {#sec006}
---------------------------

At inclusion, schistosomiasis was evaluated using the microscopic urine filtration method as described \[[@pntd.0008464.ref017]\]. Participants were classified as *Sh*^*+*^ if at least one egg was detected, and as *Sh*^*-*^ if three consecutive urine screenings were negative. The infection with STH, including *Ascaris lumbricoides*, *Trichuris trichiura* and *Necator americanus* hookworms, was determined in fresh stool samples using the Kato-Katz technique \[[@pntd.0008464.ref017]\]. A modified agar coproculture protocol was used for the detection of hookworms and *Strongyloides* larva. A thick blood smear was analyzed by microscopic examination for detecting *Plasmodium falciparum* parasites \[[@pntd.0008464.ref017]\].

Hematological and biochemical analysis {#sec007}
--------------------------------------

Hematological analysis was performed using an ABX Pentra 60 hematology system (Horiba Medical). For biochemical analysis, serum alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), glucose, total cholesterol (TC), high density lipoprotein-cholesterol (HDL-c) and triglycerides (TG) were measured on a Modular Analytics P-800 system (Roche Diagnostics). Low density lipoprotein-cholesterol (LDL-c) was calculated applying the Friedewald calculation. Serum insulin and C-peptide were measured on an Immulite 2500 automated system (Siemens Healthcare Diagnostics). High-sensitivity C-reactive protein (hsCRP) was measured using a multiplex array (Meso Scale Discovery). TIgE was measured by ELISA, as previously described \[[@pntd.0008464.ref016]\]. HOMA-IR was calculated as fasting insulin (mU/L) x fasting glucose (mmol/L)/22.5.

Circulating anodic antigen assay {#sec008}
--------------------------------

Serum Circulating Anodic Antigen (CAA) concentrations were determined by the up-converting phosphor lateral flow (UCP-LF) assay as previously described \[[@pntd.0008464.ref019]\]. Standards with known CAA concentrations were included to generate a calibration curve to calculate individual CAA levels and to validate the threshold of the assay; the maintained lower limit of detection was 10 pg/ml.

Serum lipidomics {#sec009}
----------------

Lipids were extracted from 100 μL of serum by the methyl-tert-butylether method and analyzed using Lipidyzer, a direct infusion-tandem mass spectrometry (DI-MS/MS)-based platform (Sciex, Redwood City, California). Lipid concentrations were expressed as nmol/g of serum.

Statistical analysis {#sec010}
--------------------

The statistical analysis was carried out using SPSS 23.0 software package (SPSS Inc) or GraphPad prism 8.3 (GraphPad Software). Quantitative variables were reported as mean and standard deviation (SD) if normally distributed, otherwise they were expressed as median and interquartile range (IQR) and log-transformed for analysis. Unpaired *t*-tests were used to compare study groups. Adjustment for confounding factors was done by multivariate analysis using linear regression, and the differences between groups were expressed as mean and 95% confidence interval (CI). Odd ratios were calculated using multiple logistic regression analysis. One-Way ANOVA with Tukey's post hoc test for multiple comparisons was used to compare the significant differences among the CAA stratified groups. Two-Way ANOVA with Tukey's *post hoc* test for multiple comparisons was used for lipidomic analyses of individual lipid species belonging to the same lipid class. *P* values \<0.05 were considered to be statistically significant.

Results {#sec011}
=======

Study population characteristics {#sec012}
--------------------------------

The anthropometric characteristics of the study population and the hematological and serum biochemical parameters measured at inclusion are shown in [Table 1](#pntd.0008464.t001){ref-type="table"}. Based on urine egg count, 39 participants on a total of 71 individuals (55%) were found positive for *S*. *haematobium* and, among them, 7 were also co-infected with at least one STH species (17.9%). There were no differences in age, gender, BMI, and serum levels of hs-CRP, ALAT and ASAT between the two groups ([Table 1](#pntd.0008464.t001){ref-type="table"}), whereas a significant increase in both serum total IgE levels (+54%;*P* = 0.025) and blood eosinophils (+57%;*P* = 0.028) was observed in *S*. *haematobium*-infected individuals (*Sh*^*+*^).

10.1371/journal.pntd.0008464.t001

###### Characteristics of the study population.

![](pntd.0008464.t001){#pntd.0008464.t001g}

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                        *S*. *haematobium*\      *S*. *haematobium*\       *P*-value     Mean difference adjusted for age, sex, BMI and other helminths (95% CI)   *P*-value
                                                                        negative\                positive\                                                                                                         
                                                                        (n = 32)                 (n = 39)                                                                                                          
  --------------------------------------------------------------------- ------------------------ ------------------------- ------------- ------------------------------------------------------------------------- -----------
  **Age (year)** (mean, range)                                          **35.7** (18--63)        **34.5** (18--63)         0.68                                                                                    

  **Male (%)**                                                          **43.8**                 **48.7**                                                                                                          

  **BMI (kg/m**^**2**^**)** (mean, SD)                                  **26.8** (6.9)           **25.6** (4.5)            0.41                                                                                    

  ***S*. *haematobium* urine eggs** (median, IQR)                       **0** (0--0)             **12** (4--63)            **\<0.001**                                                                             

  **Other helminths (%)**                                               **0**                    **17.9**                                                                                                          

  *** Ascaris lumbricoides* (%)**                                       **0**                    **2.6**                                                                                                           

  *** Trichuris trichiura* (%)**                                        **0**                    **10.3**                                                                                                          

  *** Necator americanus* (%)**                                         **0**                    **7.7**                                                                                                           

  *** Strongyloides (%)***                                              **0**                    **2.6**                                                                                                           

  **TIgE (IU/L)** (median, IQR)[\*](#t001fn002){ref-type="table-fn"}    **6216** (1545--17478)   **10476** (6570--19740)   **0.034**     **3226** (-1584, 8035)                                                    0.19

  **Eosinophils (%)** (mean, SD)[\*](#t001fn002){ref-type="table-fn"}   **10.3** (8.2)           **18.0** (9.6)            **0.011**     **7.1** (0.9, 13.4)                                                       **0.025**

  **hs-CRP (mg/L)** (median, IQR)                                       **1.91** (0.49--4.52)    **1.71** (0.68--4.07)     0.78          **-0.12** (-0.81, 0.56)                                                   0.72

  **ALAT (GPT, U/L)** (mean, SD)                                        **19.2** (11.9)          **17.1** (9.3)            0.42          **-3.3** (-8.4, 1.8)                                                      0.20

  **ASAT (GOT, U/L)** (mean, SD)                                        **26.4** (10.1)          **24.2** (7.0)            0.29          **-2.9** (-7.0, 1.2)                                                      0.16

  **Glucose (mmol/L)** (mean, SD)                                       **4.61** (1.06)          **4.52** (0.67)           0.66          **-0.14** (-0.57, 0.28)                                                   0.51

  **Insulin (mU/L)** (median, IQR)                                      **4.45** (2.74--7.21)    **4.54** (2.91--9.62)     0.91          **0.06** (-0.43, 0.55)                                                    0.81

  **C-peptide (nmol/L)** (median, IQR)                                  **0.41** (0.32--0.61)    **0.36** (0.27--0.62)     0.59          **-0.05** (-0.38, 0.27)                                                   0.75

  **HOMA-IR** (median, IQR)                                             **0.94** (0.52--1.32)    **1.00** (0.57--1.80)     0.87          **0.06** (-0.45, 0.58)                                                    0.80

  **TC (mmol/L)** (mean, SD)                                            **4.42** (0.84)          **4.01** (0.81)           **0.037**     **-0.30** (-0.68, -0.08)                                                  0.11

  **HDL-C (mmol/L)** (mean, SD)                                         **1.44** (0.40)          **1.18** (0.31)           **0.003**     **-0.24** (-0.43, -0.06)                                                  **0.009**

  **LDL-C (mmol/L)** (mean, SD)                                         **2.56** (0.73)          **2.50** (0.78)           0.74          **-0.04** (-0.31, 0.38)                                                   0.84

  **TG (mmol/L)** (mean, SD)                                            **0.93** (0.50)          **0.72** (0.21)           **0.031**     **-0.20** (-0.39, -0.03)                                                  **0.022**
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Normally distributed data are presented as means +/- standard deviation (SD) and non-normally distributed data as median +/- interquartile range (IQR). Adjusted mean difference for TIgE, hs-CRP, Insulin, C-peptide, and HOMA-IR were anti-log transformed.

\*, some values are missing (n = 31 in *Sh*- for TIgE; n = 18 in *Sh*- and n = 30 in *Sh*+ for eosinophils).Abbreviations: BMI: body mass index, TIgE: total immunoglobulin E, hs-CRP: high-sensitivity C-reactive protein, ALAT: alanine aminotransferase, ASAT: aspartate aminotransferase, HOMA-IR: HOmeostatic Model Assessment for Insulin Resistance, TC: total cholesterol, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein cholesterol, TG: triglycerides.

Effects of *S*. *haematobium* infection on HOMA-IR, circulating cholesterol and triglyceride levels {#sec013}
---------------------------------------------------------------------------------------------------

To assess the impact of *S*. *haematobium* infection on glucose homeostasis and insulin resistance, the serum levels of glucose, insulin and C-peptide were measured in *Sh*^*-*^ and *Sh*^*+*^ individuals and the HOMA-IR index calculated. As shown in [Table 1](#pntd.0008464.t001){ref-type="table"}, these parameters were not different between the two groups. Next, the effect of *S*. *haematobium* infection on lipid homeostasis was assessed and serum TC (-9%;*P* = 0.037), HDL-C (-18%;*P* = 0.003) and TG (-23%;*P =* 0.031) levels were found to be lower in *Sh*^*+*^ when compared to *Sh*^*-*^ individuals. After adjustment for age, sex, BMI, and other helminth infection, we observed similar effects, although it remained only significant for HDL-C and TG ([Table 1](#pntd.0008464.t001){ref-type="table"}). Multivariate logistic regression analysis was also performed to assess the influence of S. haematobium infection on the abovementioned metabolic parameters and gave similar outcomes ([S1 Table](#pntd.0008464.s003){ref-type="supplementary-material"}). Importantly, the reductions in serum TC, HDL-C and TG levels were mostly seen in overweight/obese infected individuals when the population was stratified according to low/normal (\<25) or high (\>25) BMI ([Table 2](#pntd.0008464.t002){ref-type="table"}). Of note, removing the 7 Sh^+^ individuals with other helminth infection from the analyses has only marginal impact on the results and does not affect our conclusions.

10.1371/journal.pntd.0008464.t002

###### Characteristics of the study population stratified according to body mass index.

![](pntd.0008464.t002){#pntd.0008464.t002g}

                                                                        BMI \<25                 BMI \>25                                                                                                                                                             
  --------------------------------------------------------------------- ------------------------ ------------------------- ------------- ------------------------- ------ ------------------------ ------------------------- ------------- -------------------------- -----------
  **Age (year)** (mean, range)                                          **34.3** (18--63)        **34.5** (18--58)         0.96                                           **37.4** (19--49)        **34.5** (18--63)         0.45                                     
  **Male (%)**                                                          **41.2**                 **50.0**                                                                 **46.7**                 **47.1**                                                           
  **BMI (kg/m**^**2**^**)** (mean, SD)                                  **21.6** (2.4)           **22.2** (1.8)            0.40          **0.8** (-0.7, 2.2)       0.30   **32.6** (5.6)           **30.0** (3.0)            0.11          **-2.8** (-5.8, 0.2)       0.06
  ***S*. *haematobium* urine eggs** (median, IQR)                       **0**                    **10** (4--62)            **\<0.001**                                    **0**                    **30** (5--59)            **\<0.001**                              
  **Other helminths (%)**                                               **0**                    **13.6**                                                                 **0**                    **23.5**                                                           
  *** Ascaris lumbricoides* (%)**                                       **0**                    **0**                                                                    **0**                    **5.9**                                                            
  *** Trichuris trichiura* (%)**                                        **0**                    **4.5**                                                                  **0**                    **17.6**                                                           
  *** Necator americanus* (%)**                                         **0**                    **9.1**                                                                  **0**                    **5.9**                                                            
  *** Strongyloides* (%)**                                              **0**                    **4.5**                                                                  **0**                    **0**                                                              
  **TIgE (IU/L)** (median, IQR)[\*](#t002fn002){ref-type="table-fn"}    **5912** (1446--19547)   **10470** (5589--21261)   0.16          **2156** (-4263, 8576)    0.50   **6562** (1447--11527)   **10476** (6899--18669)   0.07          **3916** (-4020, 11852)    0.32
  **Eosinophils (%)** (mean, SD)[\*](#t002fn002){ref-type="table-fn"}   **12.0** (9.0)           **20.3** (9.8)            0.08          **8.3** (-2.0, 18.6)      0.11   **9.2** (8.0)            **15.1** (8.7)            0.12          **5.6** (-3.1. 14.2)       0.19
  **hs-CRP (mg/L)** (median, IQR)                                       **2.15** (0.55--6.82)    **1.19** (0.52--3.42)     0.28          **-0.52** (-1.50, 0.46)   0.29   **1.79** (0.46--3.78)    **2.63** (1.06--5.96)     0.28          **0.31** (-0.62, 1.24)     0.50
  **ALAT (GPT, U/L)** (mean, SD)                                        **17.0** (10.6)          **16.2** (5.9)            0.76          **-1.1** (-6.8., 4.6)     0.69   **21.6** (13.2)          **18.3** (12.5)           0.47          **-6.2** (-15.8.9, 3.3)    0.19
  **ASAT (GOT, U/L)** (mean, SD)                                        **25.6** (10.5)          **23.9** (6.1)            0.53          **-2.5** (-8.0, 3.0)      0.36   **27.3** (10.0)          **24.7** (8.2)            0.42          **-3.5** (-10.3, 3.2)      0.29
  **Glucose (mmol/L)** (mean, SD)                                       **4.47** (1.19)          **4.60** (0.62)           0.66          **0.10** (-0.50, 0.70)    0.73   **4.76** (0.91)          **4.41** (0.73)           0.23          **-0.49** (-1.14, 0.15)    0.13
  **Insulin (mU/L)** (median, IQR)                                      **4.55** (2.78--7.93)    **5.08** (2.91--9.88)     0.77          **0.06** (-0.59, 0.71)    0.84   **4.22** (2.68--7.16)    **3.76** (2.44--8.55)     0.87          **0.06** (-0.75, 0.87)     0.88
  **C-peptide (nmol/L)** (median, IQR)                                  **0.38** (0.31--0.58)    **0.43** (0.29--0.68)     0.93          **0.02** (-0.44, 0.49)    0.92   **0.42** (0.32--1.07)    **0.32** (0.26--0.54)     0.36          **-0.12** (-0.63, 0.39)    0.63
  **HOMA-IR** (median, IQR)                                             **0.93** (0.49--1.33)    **1.10** (0.59--2.01)     0.58          **0.15** (-0.54, 0.83)    0.66   **0.99** (0.52--1.32)    **0.80** (0.44--1.71)     0.73          **-0.04** (-0.89, 0.81)    0.92
  **TC (mmol/L)** (mean, SD)                                            **4.11** (0.75)          **3.98** (0.70)           0.60          **-0.06** (-0.49, 0.36)   0.76   **4.78** (0.81)          **4.04** (0.96)           **0.025**     **-0.52** (-1.16, 0.12)    0.11
  **HDL-C (mmol/L)** (mean, SD)                                         **1.43** (0.47)          **1.21** (0.36)           0.12          **-0.23** (-0.52, 0.07)   0.12   **1.46** (0.32)          **1.13** (0.22)           **0.002**     **-0.27** (-0.48, -0.06)   **0.013**
  **LDL-C (mmol/L)** (mean, SD)                                         **2.30** (0.54)          **2.43** (0.69)           0.52          **0.21** (-0.16, 0.57)    0.26   **2.85** (0.82)          **2.59** (0.89)           0.39          **-0.10** (-0.74, 0.53)    0.74
  **TG (mmol/L)** (mean, SD)                                            **0.83** (0.24)          **0.74** (0.23)           0.22          **-0.10** (-0.25, 0.05)   0.18   **1.05** (0.69)          **0.70** (0.18)           0.07          **-0.31** (-0.66, 0.05)    0.08

Normally distributed data are presented as means +/- standard deviation (SD) and non-normally distributed data as median +/- interquartile range (IQR). Adjusted mean difference for TIgE, hs-CRP, Insulin, C-peptide and HOMA-IR were anti-log transformed.

\*, some values are missing (for TIgE n = 14 in BMI\>25 and *Sh-*; for eosinophils n = 6 in BMI\<25 and *Sh-*, n = 17 in BMI\<25 and *Sh+* and n = 9 in BMI\>25 and *Sh-*). Abbreviations: BMI: body mass index; TIgE: total immunoglobulin E; hs-CRP: high-sensitivity C-reactive protein; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HOMA-IR: HOmeostatic Model Assessment for Insulin Resistance; TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglycerides.

Association between *S*. *haematobium* infection intensity and serum lipid levels {#sec014}
---------------------------------------------------------------------------------

When measuring serum CAA concentrations, a highly sensitive method for assessing infection intensity \[[@pntd.0008464.ref020]\], we found that a significant fraction of *Sh*^*-*^ individuals (34%) scored positive for CAA (\>10pg/ml), indicating active worm infection, whereas few *Sh*^*+*^ individuals (9%) returned a CAA concentration below the threshold value of the assay ([S2 Fig](#pntd.0008464.s002){ref-type="supplementary-material"}).

After re-analysis of the data using the serum CAA levels as diagnostic criteria, we found that *S*. *haematobium* infection was still associated with significant increase in blood eosinophils (+70%;*P* = 0.040) and reduction in serum TC (-10%;*P* = 0.020) levels after adjustment for age, sex and BMI ([Table 3](#pntd.0008464.t003){ref-type="table"}). Multivariate logistic regression analysis gave similar outcomes ([S2 Table](#pntd.0008464.s004){ref-type="supplementary-material"}). Similar outcomes were found when stratifying the population according to the intensity of the infection using CAA levels, with some non-significant trends for reduced serum levels also observed for HDL-C, LDL-C and TG ([S3 Table](#pntd.0008464.s005){ref-type="supplementary-material"}). When stratifying the population according to BMI, a significant decrease in serum TC levels was observed only in overweight/obese infected individuals ([S4 Table](#pntd.0008464.s006){ref-type="supplementary-material"}). In line with this, significant negative correlations were found between serum CAA and TC, HDL-C, LDL-C and TG levels, respectively, in both non-stratified whole population and obese/overweight individuals but not in lean subjects ([Fig 1](#pntd.0008464.g001){ref-type="fig"}).

10.1371/journal.pntd.0008464.t003

###### Characteristics of the study population stratified according to CAA levels.
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  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                        CAA\<10 pg/ml\          CAA\>10 pg/ml\            *P*-value   Mean difference adjusted for age, sex and BMI (95% CI)   *P*-value
                                                                        (n = 21)                (n = 50)                                                                                       
  --------------------------------------------------------------------- ----------------------- ------------------------- ----------- -------------------------------------------------------- -----------
  **Age (year)** (mean, range)                                          **39.2** (18--63)       **33.3** (18--63)         0.07                                                                 

  **Male (%)**                                                          **42.9**                **48**                                                                                         

  **BMI (kg/m**^**2**^**)** (mean, SD)                                  **27.0** (6.8)          **25.7** (5.2)            0.40                                                                 

  **TIgE (IU/L)** (median, IQR)[\*](#t003fn002){ref-type="table-fn"}    **5559** (700--17761)   **10207** (6104--18408)   **0.025**   **4485** (-618, 9588)                                    0.08

  **Eosinophils (%)** (mean, SD)[\*](#t003fn002){ref-type="table-fn"}   **9.9** (7.5)           **17.3** (9.8)            **0.028**   **6.9** (0.3, 13.4)                                      **0.040**

  **hs-CRP (mg/L)** (median, IQR)                                       **1.66** (0.50--2.69)   **2.27** (0.68--5.07)     0.24        **0.58** (-0.13, 1.29)                                   0.11

  **ALAT (GPT, U/L)** (mean, SD)                                        **16.3** (7.3)          **18.8** (11.7)           0.38        **3.3** (-1.6, 8.2)                                      0.18

  **ASAT (GOT, U/L)** (mean, SD)                                        **23.0** (5.3)          **26.2** (9.5)            0.08        **2.43** (-1.9, 6.8)                                     0.20

  **Glucose (mmol/L)** (mean, SD)                                       **4.44** (1.12)         **4.61** (0.73)           0.44        **0.30** (-0.15, 0.75)                                   0.18

  **Insulin (mU/L)** (median, IQR)                                      **4.55** (2.76--7.19)   **4.44** (2.89--9.63)     0.94        **0.09** (-0.43, 0.61)                                   0.73

  **C-peptide (nmol/L)** (median, IQR)                                  **0.41** (0.31--0.69)   **0.37** (0.27--0.62)     0.33        **-0.12** (-0.47, 0.22)                                  0.48

  **HOMA-IR** (median, IQR)                                             **0.94** (0.46--1.22)   **0.95** (0.57--1.80)     0.71        **-0.19** (-0.68, 0.29)                                  0.43

  **TC (mmol/L)** (mean, SD)                                            **4.62** (0.90)         **4.01** (0.80)           **0.005**   **-0.47** (-0.86, -0.07)                                 **0.020**

  **HDL-C (mmol/L)** (mean, SD)                                         **1.42** (0.38)         **1.24** (0.36)           0.06        **-0.18** (-0.38, 0.02)                                  0.07

  **LDL-C (mmol/L)** (mean, SD)                                         **2.78** (0.82)         **2.42** (0.70)           0.06        **-0.24** (-0.61, 0.12)                                  0.19

  **TG (mmol/L)** (mean, SD)                                            **0.91** (0.56)         **0.78** (0.28)           0.31        **-0.09** (-0.28, 0.10)                                  0.34
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Normally distributed data are presented as means +/- standard deviation (SD) and non-normally distributed data as median +/- interquartile range (IQR). Adjusted mean difference for TIgE, hs-CRP, Insulin, C-peptide and HOMA-IR were anti-log transformed.

\*, some values are missing (n = 49 in CAA\>10pg/ml for TIgE; n = 11 in CAA\<10pg/ml and n = 34 in CAA\>10pg/ml for eosinophils). Abbreviations: BMI: body mass index; TIgE: total immunoglobulin E; CAA: circulating anodic antigen; hs-CRP: high-sensitivity C-reactive protein; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HOMA-IR: HOmeostatic Model Assessment for Insulin Resistance; TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglycerides.

![Associations between intensity of *S*. *haematobium* infection assessed by circulating anodic antigen levels and serum lipid parameters.\
The correlations between serum CAA and TC, HDL-C, LDL-C and TG were shown for the whole population (\[n = 71\], a) and for lean (BMI\<25 \[n = 39\], b) and overweight/obese (BMI\>25 \[n = 32\], c) individuals. *Sh*, *Schistosoma haematobium;* CAA, Circulating Anodic Antigen; TC, Total Cholesterol; HDL-C, High-Density Lipoprotein-Cholesterol; LDL-C, Low-Density Lipoprotein-Cholesterol; TG, Triglycerides.](pntd.0008464.g001){#pntd.0008464.g001}

In order to further investigate the effects of *S*. *haematobium* infection on circulating lipids and lipoproteins, we performed comprehensive quantitative lipidomic analysis of serum from lean and overweight/obese individuals. The levels of the individual lipid species ([S5 Table](#pntd.0008464.s007){ref-type="supplementary-material"}) belonging to the same lipid class were summed up for an approximate measure of the total serum levels for each lipid class ([Fig 2A--2B](#pntd.0008464.g002){ref-type="fig"}). We confirmed that total cholesteryl ester (CE) and TG levels were significantly higher in overweight/obese individuals when compared to lean subjects. A significant reduction of CE was observed in both groups of infected subjects but only correlated with the intensity of infection in obese/overweight individuals. Total phosphatidylcholine (PC) and TG levels were also found to be reduced in obese/overweight but not lean infected individuals ([Fig 2A--2B](#pntd.0008464.g002){ref-type="fig"}). When zooming into the individual lipid species, *S*. *haematobium* infection was seen to be associated with a significant reduction of 6 PCs ([Fig 2C](#pntd.0008464.g002){ref-type="fig"}), 3 CEs ([Fig 2D](#pntd.0008464.g002){ref-type="fig"}) and 6 TGs ([Fig 2E](#pntd.0008464.g002){ref-type="fig"}), especially among the most abundant species which are also found to be increased in overweight/obese individuals (*e*.*g*. PC(16:0/18:1), CE (18:2) and TG (52:2))\[[@pntd.0008464.ref021], [@pntd.0008464.ref022]\].

![Effects of *S*. *haematobium* infection on serum lipid profiles in lean and obese subjects.\
Lipidomics analysis was performed using the Lipidyzer platform on serum from lean (BMI\<25, a) and overweight/obese (BMI\>25, b) individuals, and the data for the lipid classes (a) and for the various PC (c), CE (d) and TG (e) species were stratified in each population according to 'below detection threshold' (\<10pg/ml), 'medium/high' (10\<CAA\<3000pg/ml) or 'high' (\>3000pg/ml) CAA levels. PC, Phosphatidylcholine; PE, Phosphatidylethanolamine; LPC, Lysophosphatidylcholine; LPE, Lysophosphatidylethanolamine; SM, Sphingomyelin; CE, Cholesterylester; DG, Diglycerides; TG, Triglycerides; FFA, Free-fatty acids. \*, p\<0.05 *versus* CAA \< 10; \#, p\<0.05 *versus* BMI \<25.](pntd.0008464.g002){#pntd.0008464.g002}

Discussion {#sec015}
==========

The main objective of the present study was to investigate the effects of *S*. *haematobium* infection on metabolic outcomes, especially on whole-body lipid/lipoprotein homeostasis, in lean and overweight/obese individuals residing in a highly endemic rural area. Although no effect of *S*. *haematobium* infection was observed on HOMA-IR, whatever the BMI status, a strong reduction in serum TC levels was consistently observed in infected individuals. Furthermore, negative correlations were also observed between the intensity of active *S*. *haematobium* infection and the circulating levels of TC, HDL-c LDL-c, TG, and some lipid species associated with cholesterol-rich lipoprotein particles in overweight/obese individuals. Altogether, our findings showed for the first time that *S*. *haematobium* infection is associated with improved circulating lipid profiles in humans, especially in overweight/obese individuals.

The lowering effect of *S*. *haematobium* infection on serum TC and cholesterol levels observed in our study is in line with the few cross-sectional investigations conducted so far in countries endemic for other helminth species. Wiria *et al*. have indeed shown that infection with the soil-transmitted helminths *Necator americanus*, *Ascaris lumbricoides* and *Trichuris trichiura* was associated with reduced serum levels of TC and HDL-c in lean Indonesian individuals from Flores Island \[[@pntd.0008464.ref023]\]. Duan *et al*. have also recently reported that serum TG, TC and LDL-c levels were significantly lower in lean Chinese subjects with chronic *S*. *japonicum* infection when compared to uninfected individuals \[[@pntd.0008464.ref024]\]. Finally, during the preparation of the manuscript, the results of a study investigating the effects of *S*. *mansoni* infection on metabolic outcomes in the framework of the LaVIISWA trial conducted in the highly-endemic region of Lake Victoria in Uganda became available \[[@pntd.0008464.ref025]\]. Interestingly, a negative association between the intensity of *S*. *mansoni* infection and serum TC, HDL-c, LDL-c and TG levels was found \[[@pntd.0008464.ref025]\]. Moreover, community-wide intensive anthelminthic treatment that resulted in lower *S*. *mansoni* prevalence was also associated with a trend towards increased TC and LDL-c, suggesting that deworming might revert some of the effects induced by helminth infection on lipid profile \[[@pntd.0008464.ref025]\]. However, it is worth to mentioning that our study is the first one investigating the impact of helminth infection in overweight/obese individuals, who have elevated lipid/cholesterol levels and higher risk for developing cardiometabolic diseases.

Several underlying mechanisms may account for the effects of helminth on lipid homeostasis, involving 1) parasitism of host dietary nutrients through hijacking of lipid resources for their own survival and reproduction, 2) alteration of gut microbiota and intestinal lipid metabolism, and 3) immune-dependent or -independent regulation of lipid metabolism in immune cells and/or peripheral tissues by helminths and their molecules.

Although adult schistosomes cannot oxidize exogenous FA \[[@pntd.0008464.ref026]\], they can use and modify host lipid for biosynthetic purposes by scavenging cholesterol and incorporating FA as phospholipids and neutral lipids in the worm eggs, notably for membrane formation of the developing miracidium \[[@pntd.0008464.ref027]\]. It is therefore tempting to speculate that part of the reduction in some lipoprotein and TG species observed in *S*. *haematobium*-infected individuals might result from their active transfer to the eggs produced by female worms and their subsequent elimination in the urine. Further studies are however required to investigate this point.

During the last decade, the gut microbiota has emerged as an important player in host metabolic homeostasis, notably by regulating intestinal lipid processing from dietary fat and nutrient metabolism in peripheral organs, but also in shaping the local and systemic immune response \[[@pntd.0008464.ref028], [@pntd.0008464.ref029]\]. Gut microbiota, via local production of various metabolites, can impact host lipid metabolism by modulating bile acid metabolism and/or a gut-brain axis involved in the control of whole-body lipid homeostasis \[[@pntd.0008464.ref030], [@pntd.0008464.ref031]\]. Since various helminth species, including *S*. *haematobium* \[[@pntd.0008464.ref032]\], have been reported to affect gut microbiota in humans \[[@pntd.0008464.ref033]\], one may hypothesize that this could underlie some of the reduction in TC and TG levels observed in helminth infected individuals, secondary to alterations of intestinal lipid absorption, hepatic cholesterol and BA biosynthesis, secretion and reuptake, or hydrolysis of TG-rich lipoproteins by peripheral metabolic tissues. Further studies would be required for investigating the putative associations between helminth-induced changes in specific gut bacterial species and serum/fecal lipid/BA profiles.

Infection with schistosomes is associated with eosinophilia, parasite-specific IgE and elevated type-2 cytokines, which are all hallmarks of a T~H~2 immune response \[[@pntd.0008464.ref010], [@pntd.0008464.ref034]\]. One may speculate that some of the beneficial effects observed on serum lipid profile from obese/overweight individuals could result from this helminth-induced immunomodulation through direct or indirect on metabolic organs. The liver plays an essential role in lipid/cholesterol metabolism, notably by regulating *de novo* lipogenesis, cholesterol biosynthesis and VLDL-TG secretion, and facilitating the clearance of circulating HDL-c via selective uptake through membrane scavenger receptors. Interestingly, type-2 cytokines, such as IL-4 and IL-13, have been shown to regulate hepatic metabolism in rodents through direct interaction with their cognate receptors expressed on hepatocytes \[[@pntd.0008464.ref035], [@pntd.0008464.ref036]\]. This type-2 micro-environment could also have some impact on lipid metabolism in other peripheral organs, notably in AT through modulation of TG lipolysis/lipogenesis. It is also worth mentioning that some of the *S*. *haematobium* worm- and/or egg-derived molecules released inside the host may also contribute to tissue-specific modulation of lipid metabolism through immune-independent direct interaction with metabolic cells \[[@pntd.0008464.ref011], [@pntd.0008464.ref037]\]. Furthermore, intracellular nutrient metabolism has been shown to be central in the regulation of immune cell activation, differentiation and function \[[@pntd.0008464.ref038], [@pntd.0008464.ref039]\]. As such, one may speculate that the decrease in serum lipid levels observed in *S*. *haematobium*-infected individuals may also partly result from increased FA and cholesterol metabolism by various circulating and/or tissue-resident immune cells secondary to helminth-induced host immunomodulation, as reported for example in hepatic macrophages from infected mice \[[@pntd.0008464.ref040]\].

The main limitations of our study are based on its observational nature, which prevents firm conclusions on causal relationship, and the relatively small sample size, especially after stratification according to BMI or CAA levels. Future studies involving larger cohort of lean and obese individuals and/or deworming intervention using anti-helminthic drug in such population would be required. In contrast to what has been reported with STH \[[@pntd.0008464.ref012], [@pntd.0008464.ref013], [@pntd.0008464.ref016]\], we did not find any association between *S*. *haematobium* infection and improved whole-body insulin resistance as assessed by HOMA-IR. This discrepancy could be explained by differences in helminth species but also eventually in age and/or lifestyle of the population studied, notably their nutritional habits. Furthermore, past infections with *S*. *haematobium* could have already imprinted their effect on insulin sensitivity, masking the influence of current infection. In this regard, trials where anthelminthic treatment is used or controlled human infection in naïve individuals with various helminth species \[[@pntd.0008464.ref041]--[@pntd.0008464.ref043]\] can better answer this question.

Supporting information {#sec016}
======================

###### Flow chart of study participants enrolment.

Sh, *Schistosoma haematobium*; STH, Soil-transmitted helminths; BMI, Body Mass Index.

(TIF)

###### 

Click here for additional data file.

###### Serum CAA levels in urine egg negative and positive individuals.

The serum CAA concentrations were measured in Sh- and Sh+ individuals diagnosed by presence of urine eggs (a), and the data were stratified in each population according to 'below detection threshold' (\<10pg/ml), 'medium/high' (10\<CAA\<3000pg/ml) or 'high' (\>3000pg/ml) CAA levels (b). The correlation between serum CAA levels and urine *S*. *haematobium* egg counts (c) in the whole population was plotted.

(TIF)

###### 

Click here for additional data file.

###### Multiple logistic regression analysis on effect of *Schistosoma haematobium* infection diagnosed by urine egg microscopy on various metabolic parameters.

Abbreviations: CI: confidence interval; OR: Odd ratio; TIgE: total immunoglobulin E; hs-CRP: high-sensitivity C-reactive protein; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HOMA-IR: HOmeostatic Model Assessment for Insulin Resistance; TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglyceride.

(DOCX)

###### 

Click here for additional data file.

###### Multiple logistic regression analysis on effect of *Schistosoma haematobium* infection diagnosed by serum CAA levels on various metabolic parameters.

Abbreviations: CI: confidence interval; OR: Odd ratio; TIgE: total immunoglobulin E; hs-CRP: high-sensitivity C-reactive protein; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HOMA-IR: HOmeostatic Model Assessment for Insulin Resistance; TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglyceride.

(DOCX)

###### 

Click here for additional data file.

###### Characteristics of the study population stratified according to CAA range.

Normally distributed data are presented as means +/- standard deviation (SD) and non-normally distributed data as median +/- interquartile range (IQR). \*, some values are missing (for TIgE n = 36 in 10\<CAA\<3000pg/ml; for eosinophils n = 11 in CAA\<10pg/ml, n = 24 in 10\<CAA\<3000pg/ml and n = 10 in CAA\>3000pg/ml). Abbreviations: BMI: body mass index; TIgE: total immunoglobulin E; CAA: circulating anodic antigen; hs-CRP: high-sensitivity C-reactive protein; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HOMA-IR: HOmeostatic Model Assessment for Insulin Resistance; TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglyceride

(DOCX)

###### 

Click here for additional data file.

###### Characteristics of the study population stratified according to CAA levels and body mass index.

Normally distributed data are presented as means +/- standard deviation (SD) and non-normally distributed data as median +/- interquartile range (IQR). Adjusted mean difference for TIgE, hs-CRP, Insulin, C-peptide and HOMA-IR were anti-log transformed. \*, some values are missing (for TIgE n = 21 in BMI\>25 and CAA\>10pg/ml, for eosinophils n = 4 in BMI\<25 and CAA\<10pg/ml, n = 19 in BMI\<25 and CAA\>10pg/ml, n = 7 in BMI\>25 and CAA\<10pg/ml and n = 15 in BMI\>25 and CAA\>10pg/ml). Abbreviations: BMI: body mass index; TIgE: total immunoglobulin E; CAA: circulating anodic antigen; hs-CRP: high-sensitivity C-reactive protein; ALAT: alanine aminotransferase; ASAT: aspartate aminotransferase; HOMA-IR: HOmeostatic Model Assessment for Insulin Resistance; TC: total cholesterol; HDL-C: high density lipoprotein-cholesterol; LDL-C: low density lipoprotein cholesterol; TG: triglycerides.

(DOCX)

###### 

Click here for additional data file.

###### Serum lipidomics in subjects stratified according to CAA levels.

Data are presented as means (+/- SD). Abbreviations: CAA: circulating anodic antigen; PC: Phosphatidylcholine; PE: Phosphatidylethanolamine; LPC: Lysophosphatidylcholine; LPE: Lysophosphatidylethanolamine; SM: Sphingomyelin; CE: Cholesterylester; DG: Diglycerides; TG: Triglycerides; FFA: Free-fatty acids.

(DOCX)

###### 

Click here for additional data file.
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Dear Dr. Guigas,

Thank you very much for submitting your manuscript \"Schistosoma haematobium infection is associated with lower serum cholesterol levels and improved lipid profile in overweight/obese individuals\" for consideration at PLOS Neglected Tropical Diseases. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

This study provides insight into the timely topic of helminth induced modulation of host metabolism. The reviewers are overall enthusiastic about the manuscript, but have a few minor issues that need to be addressed for acceptance. Please address the points raised by Reviewers 2 and 3 on sample size, co-infections, the use of CAA, and expanding the discussion to align the current study with the recent literature. As well as addressing the mislabeling raised by reviewers 1 and 3.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.  

When you are ready to resubmit, please upload the following:

\[1\] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. 

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

\[2\] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.
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Keke Fairfax, PhD
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This study provides insight into the timely topic of helminth induced modulation of host metabolism. The reviewers are overall enthusiastic about the manuscript, but have a few minor issues that need to be addressed for acceptance. Please address the points raised by Reviewers 2 and 3 on sample size, co-infections, the use of CAA, and expanding the discussion to align the current study with the recent literature. As well as addressing the mislabeling raised by reviewers 1 and 3.

Reviewer\'s Responses to Questions

**Key Review Criteria Required for Acceptance?**

As you describe the new analyses required for acceptance, please consider the following:

**Methods**

-Are the objectives of the study clearly articulated with a clear testable hypothesis stated?

-Is the study design appropriate to address the stated objectives?

-Is the population clearly described and appropriate for the hypothesis being tested?

-Is the sample size sufficient to ensure adequate power to address the hypothesis being tested?

-Were correct statistical analysis used to support conclusions?

-Are there concerns about ethical or regulatory requirements being met?

Reviewer \#1: Methods are appropriate and the study design addresses the stated objectives. Although the population size is small

Reviewer \#2: The authors have performed a well designed, reasonably well powered and thorough analysis of metabolic parameters in each cohort. The statistical analysis is appropriate and of excellent standard. The study is novel in regards to the depth of analysis, and the human population (ie concurrent analysis of obese and lean individuals +/- worms.

One confounder is that is addition to S. hematobium (Sh), 7 of the participants also had another helminth infection. This is acknowledged by the authors, but it means that within their Sh+ cohort, there are people with Sh only, and some people with Sh plus other parasites. This may have implications for their results, and the authors should present some data whether the presence of a con-infection leads to quantitative differences in any of the key parameters.

Reviewer \#3: Study population:

The authors do not mention how the sample size was calculated. Please include this information in the Methods section. One of the main limitations of this study is the sample size. This information is crucial to determine if the sample size is appropriate, and therefore the conclusions can be supported.

Individuals Sh+ were negative for STH and Plasmodium? It is not clear in the Methods if co-infections were excluded. Line 112: for treatment of Sh+ individuals, parasitological (presence of eggs in urine) and CAA results were considered?

Hematological and biochemical analysis:

I strongly recommend including the reference values of the biochemical parameters for your study population as supplemental material.

Quantitative insulin sensitivity check index (QUICKI) = 1 / (log(fasting insulin μU/mL) + log(fasting glucose mg/dL)) should be calculated and included as an additional measurement of insulin resistance.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Results**

-Does the analysis presented match the analysis plan?

-Are the results clearly and completely presented?

-Are the figures (Tables, Images) of sufficient quality for clarity?

Reviewer \#1: Results are clearly and completely presented. One aspect not addressed is the relationship of the immune response (as determined by eosinophils numbers and or %) to the lipid profile for each individual. The authors do mention in the discussion that the possible effect of IL4/IL13 on hepatocyte function may be one of the mechanisms for lowering TG. Eosinophil levels do reflect the immune response to the parasite by an individual and although the authors are correct to use CAA levels to measure intensity of parasite infection it would also be worth it I thought to measure intensity of the immune response to the Sh and lipid levels.

The \'Statistical Analysis\' paragraph is well written. These are a good choice of tests, consideration of confounding factors, and multiple testing corrections.

Tables S1 & S2 is where they show the raw Odds Ratio and confounder adjusted OR for egg and serum levels. Tables S1, S2 are very informative, and are well presented by showing both raw and adjusted results (that consider multiple important confounding factors).

Tables S3, S4, S5 are mislabelled. Table S3 summarises factors stratified by CAA range; the Eosinophil response appears to show incredibly strong correlation to stratification level, it is unfortunate they lost some measurements for Eosinophils as stated, but their choice of statistical test is well suited to different sample sizes. Table S4 shows the disparity between gender between BMI \>/\< 25 groups, showing the importance of showing adjusted OR -- It is important that the presentation of raw data is included.

Fig. 1 It is interesting when whole population the HDL-C has a significant p-value but when you split it into lean & obese there is no significant p-value in either, despite the same trend. The overall trend is clear however that serum CAA levels are associated with many cholesterol measurements in the obese category.

Fig. 2 a and b are skillfully plotted - and a statement is needed with respect to what p-values are associated to (\#/\*/\#\*) on the heatmap.

Reviewer \#2: The results are well presented and clear

Reviewer \#3: The CAA corrected data should be included in the main paper and not as supplemental materials. The authors should simplify the results and use only the CAA positive and CAA negative as the Sh+ and Sh- groups in the paper. Table 2 should be corrected using the CAA data.

Figure 1: Please include the number of patients for each analysis (whole population, BMI\<25, and BMI\>25).

Figure 2: Please include the definition of \* and \# in the figure legend.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Conclusions**

-Are the conclusions supported by the data presented?

-Are the limitations of analysis clearly described?

-Do the authors discuss how these data can be helpful to advance our understanding of the topic under study?

-Is public health relevance addressed?

Reviewer \#1: The conclusions are supported by the data and the authors have been clear about the limitations of the data. The authors discuss well the relevance of the data to human health as it relates to lipid levels in individuals with high BMI. Of course it is a big jump from this study to proposing Sh infection would have similar effects on Dutch people who have never previously encountered Sh infection.

Reviewer \#2: The authors have interpreted their results and limitations well, highlighting where their findings fit with the (rapidly growing) literature in this field relating to worms and metabolism.

There remains obvious mechanistic unknowns as to HOW Sh regulates metabolism, some more in depth analysis of cytokines, cellular immune responses and the microbiome would have been useful to understand this, but this could form the basis of future work (and is well discussed anyway).

Reviewer \#3: I recommend the authors to include a short conclusion paragraph at the end of the discussion.

Paragraph 273-292: The article by Cortes-Selva D et al. (Frontiers in Immunology 12;9:2580) should be included since it reinforces the hypothesis that Schistosoma induced Th2 response confers protection from hyperlipidemia, atherosclerosis, and glucose intolerance.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Editorial and Data Presentation Modifications?**

Use this section for editorial suggestions as well as relatively minor modifications of existing data that would enhance clarity. If the only modifications needed are minor and/or editorial, you may wish to recommend "Minor Revision" or "Accept".

Reviewer \#1: The \'Statistical Analysis\' paragraph is well written. These are a good choice of tests, consideration of confounding factors, and multiple testing corrections.

Tables S1 & S2 is where they show the raw Odds Ratio and confounder adjusted OR for egg and serum levels. Tables S1, S2 are very informative, and are well presented by showing both raw and adjusted results (that consider multiple important confounding factors).

Tables S3, S4, S5 are mislabelled. Table S3 summarises factors stratified by CAA range; the Eosinophil response appears to show incredibly strong correlation to stratification level, it is unfortunate they lost some measurements for Eosinophils as stated, but their choice of statistical test is well suited to different sample sizes. Table S4 shows the disparity between gender between BMI \>/\< 25 groups, showing the importance of showing adjusted OR -- It is important that the presentation of raw data is included.

Fig. 1 It is interesting when whole population the HDL-C has a significant p-value but when you split it into lean & obese there is no significant p-value in either, despite the same trend. The overall trend is clear however that serum CAA levels are associated with many cholesterol measurements in the obese category.

Fig. 2 a and b are skillfully plotted - and a statement is needed with respect to what p-values are associated to (\#/\*/\#\*) on the heatmap.

Reviewer \#2: (No Response)

Reviewer \#3: As mentioned above, the tables presented in the main text should be modified to include the CAA data. CAA text is more sensitive and should be considered as the \"true positive and true negatives.\" The analysis based only on the direct observation of eggs in urine does not need to be included in the main text since it contains false negatives.

QUICKI should be calculated and included in the paper.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

**Summary and General Comments**

Use this section to provide overall comments, discuss strengths/weaknesses of the study, novelty, significance, general execution and scholarship. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. If requesting major revision, please articulate the new experiments that are needed.

Reviewer \#1: This is an interesting and provocative study. I do think it would be interesting to put in a comparison of all the individual immune responses to Sh (as measured by eosinophil levels) and the effect on lipid levels.

Reviewer \#2: I think this is a timely, novel and interesting study. Some clarification as to the relative importance of S hematobium versus the other co-endemic helminths would add important supportive evidence

Reviewer \#3: Zinsou et al. observed that overweight/obese individuals infected with Schistosoma haematobium have an improved lipid profile. This manuscript is relevant to the readers of PlosNTDs, and this study is the first report that evaluated the impact of a helminth infection in overweight/obese individuals from endemic areas. The main limitation of the study is the sample size. The authors need to inform how the sample size was calculated. The manuscript is well written, but the data could be better presented. The Sh+ and Sh- groups should be divided based on CAA test since it is more sensitive than the parasitological exam (presence of eggs in urine). However, the authors present this data mostly as supplemental material.

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosntds/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, [https://pacev2.apexcovantage.com. PACE](https://pacev2.apexcovantage.com. PACE) helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>.

Data Requirements:

Please note that, as a condition of publication, PLOS\' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example see here: <http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5>.

Reproducibility:

To enhance the reproducibility of your results, PLOS recommends that you deposit laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosntds/s/submission-guidelines#loc-materials-and-methods>
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8 Jun 2020

Dear Dr. Guigas,

We are pleased to inform you that your manuscript \'Schistosoma haematobium infection is associated with lower serum cholesterol levels and improved lipid profile in overweight/obese individuals\' has been provisionally accepted for publication in PLOS Neglected Tropical Diseases.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Keke Fairfax, PhD

Deputy Editor

PLOS Neglected Tropical Diseases

Michael Hsieh

Deputy Editor

PLOS Neglected Tropical Diseases
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Your revisions have addressed the concerns raised by the reviewers.
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24 Jun 2020

Dear Dr. Guigas,

We are delighted to inform you that your manuscript, \"Schistosoma haematobium infection is associated with lower serum cholesterol levels and improved lipid profile in overweight/obese individuals,\" has been formally accepted for publication in PLOS Neglected Tropical Diseases.

We have now passed your article onto the PLOS Production Department who will complete the rest of the publication process. All authors will receive a confirmation email upon publication.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any scientific or type-setting errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript. Note: Proofs for Front Matter articles (Editorial, Viewpoint, Symposium, Review, etc\...) are generated on a different schedule and may not be made available as quickly.

Soon after your final files are uploaded, the early version of your manuscript will be published online unless you opted out of this process. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Neglected Tropical Diseases.

Best regards,

Shaden Kamhawi

co-Editor-in-Chief

PLOS Neglected Tropical Diseases

Paul Brindley

co-Editor-in-Chief

PLOS Neglected Tropical Diseases
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